

01/10/00
REQUEST FOR FILING CONTINUATION PATENT APPLICATION
(Under 37 CFR § 1.53(b))
WHITMAN BREED ABBOTT & MORGAN LLP

File No. 0039096-0030

A
jc525 U.S. PTO
09/480544
01/10/00

PRIOR APPLICATION: 08/474,927	
EXAMINER: A. Chakrabarti	ART UNIT 1655
ANTICIPATED CLASSIFICATION OF THIS APPLICATION:	
CLASS	SUBCLASS

EXPRESS MAIL	
Mailing label number:	FI46510412BUS
Date of Deposit:	January 10, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, BOX APPLICATION, Washington, D.C. 20231.	
<u>N. Gavindan.</u> (Typed or printed name of person mailing paper or fee)	
<u>[Signature]</u> (Signature of person mailing paper or fee)	

ASST. COMMISSIONER FOR PATENTS
BOX APPLICATION
WASHINGTON, D.C. 20231

Sir:

This is a Request for filing a X continuation, divisional application under 37 CFR § 1.53(b) of pending prior application Serial No. 08/474,927, filed on June 7, 1995, by Kenten et al. and currently entitled *Cycling DNA/RNA Amplification Electrochemiluminescent Probe Assay*.

1. X Enclosed is a copy of the latest inventor signed prior application, including the oath or declaration as originally filed. I hereby verify to the best of my information and belief that the attached papers are a true copy of the latest inventor signed prior application Serial No. 08/474,927 as originally filed on June 7, 1995.
2. X The filing fee is calculated on the basis of the claims existing in the prior application, less any claims cancelled by amendment at paragraph 5 below, as follows:

(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS	20	0	x \$22.00	\$ 0
INDEPENDENT CLAIMS	3	0	x \$39.00	0
MULTIPLE DEPENDENT CLAIMS(S) (IF APPLICABLE)			+ \$	0
			BASIC FEE	+ \$ 380.00
			Total of above Calculations	
			\$380.00	
Reduction by 1/2 for filing by small entity (Note: 37 CFR § 1.9, § 2.37, § 1.28).				
If applicable, verified statement must be attached or already be on file in prior application.				
			TOTAL FILING FEE	
			\$380.00	

3. X The Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 (for filing) and § 1.17 (for prosecution) which may be required with respect to the papers filed herewith, (X and also any additional such fees which may be required during the entire pendency of this application, _ and also the issue fee under 37 CFR 1.18), or credit any overpayment, to Deposit Account No. 50-0297. A duplicate copy of this sheet is enclosed.

4. a. X A check in the amount of \$380.00 is enclosed.
 b. _ The filing fee to be paid later with surcharge [pursuant to 37 CFR § 1.53(d)].

5. _ Cancel in this application original claims _____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

6. X Amend the specification by inserting before the first line the sentence:

This application is a X continuation _ division of application Serial No. 08/474,927, filed **June 7, 1995**, which is incorporated herein by reference.

[Note: If priority under 35 U.S.C. 120 involves a series of respectively copending applications, then in this amendment identify each and its relationship to its immediate predecessor.]

7. a. _ A verified statement claiming small entity status is enclosed. [Note: Such a statement may be filed within two months with a request for refund of overpayment, under 37 CFR § 1.28(a)].
 b. X A verified statement claiming small entity status was filed in the prior application, Serial No. 08/474,927, filed June 7, 1995. Status as a small entity is still proper and is desired and claimed herein.
8. a. _ Transfer the drawings from the pending prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by 37 CFR § 1.138 and before payment of issue fee.)
 b. _ New formal drawings are enclosed.
9. a. _ Priority of foreign Application No(s). _ filed on _ in _, respectively, is claimed under 35 U.S.C. 119.
 b. _ A certified copy of said foreign priority application(s) was filed in prior U.S. application Serial No. _ filed _. Acknowledgement thereof is requested.
10. X The prior application is assigned of record to IGEN International, Inc.
11. X A preliminary amendment is intended.


12. X The power of attorney in the prior application is to: Barry Evans, Reg. No. 22,802.
- a. X The power appears in the original papers in the prior application.
- b. — Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
13. — Original title and original applicant(s) of prior U.S. application, if different from above:
14. — Also enclosed: Information Disclosure Statement.
15. X Address all future communications to (may only be completed by applicant, or attorney, or agent of record):

Attention of: Barry Evans, Esq.
WHITMAN BREED ABBOTT & MORGAN LLP
200 Park Avenue
New York, New York 10166

16. X Any extension of time necessary to maintain the copendency of the prior application and to allow the timely filing of this application is hereby requested. Please charge the fee for the extension of time, if not otherwise paid, to Deposit Account No. 50-0297. A duplicate copy of this sheet is enclosed for filing in the prior application file.

Date: **January 10, 2000**

WHITMAN BREED ABBOTT & MORGAN LLP

By: 
 Barry Evans
 Reg. No. 22,802
 Pamela C. Ancona
 Reg. No. 41,494
 Attorney/Agent of record
 (or filed under 37 CFR § 1.34)
 Telephone: (212) 351-3000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES PATENT APPLICATION

Inventors : John H. Kenten
Rodger Smith

Title : RAPID NUCLEIC ACID ASSAY

Claims : 20

John W. Ryan, Esq.
Reg. No. 33,771
IGEN, Inc.
1530 East Jefferson Street
Rockville, Maryland 20852
(301) 984-8000

Rapid Nucleic Acid Assay

Field of the Invention

5 This invention relates to an enhanced process for amplifying a specific nucleic acid sequence and its rapid detection and quantitation using electrochemiluminescent labeled binding species.

Background of the Invention

10 Detection and quantitation of a specific nucleic acid sequence present in a sample is a known diagnostic method with great specificity. This specificity is based on the knowledge of the specific sequence and the generation of probes which are specific and complementary.

Methods for detection and quantitation of specific nucleic acid sequences are illustrated by the following patents: (1) U.S. Patent No. 5,130,238 is directed toward an improved process for amplifying a specific nucleic acid sequence. The improvement of the amplification process involves the
15 addition of dimethylsulfoxide (DMSO) alone or in combination with bovine serum albumin (BSA); (2) U.S. Patent No. 4,683,195 is directed toward a process for amplifying and detecting any target nucleic acid sequence contained in a nucleic acid or mixture thereof; (3) U.S. Patent No. 4,683,202 is directed toward a process for amplifying any desired specific nucleic acid sequence contained in a nucleic acid or mixture thereof; (4) U.S. Patent No. 4,486,539 is directed toward a method for identifying nucleic
20 acids by a one-step sandwich hybridization test; and (5) WO 91/02814 is directed toward a process for amplifying a specific nucleic acid sequence.

The use of highly specific nucleic acid probes is in some cases the only method which can yield accurate results when the protein is absent, such as is the case for analysis of genetic defects such as cystic fibrosis. It is also valuable in the case of a latent viral infection such as HIV1 or herpes where
25 little or no protein is produced by the infection. The great specificity of the nucleic acid probes also makes them valuable in the diagnosis of infectious agents which are difficult to identify with antibodies due to cross reaction and lack of cross reaction between isotypes of these agents. In addition, the analysis of DNA sequences allows the rapid and effective selection of a probe which will be specific this is not possible with antibody-based reagents.

30 The greatest difficulty and limitation with applying existing nucleic acid probe technology is the complexity and slow methodology for the detection of specific sequences. With the amplification of

systems which require multiple cycles of incubations and multiple washes followed by multiple incubations for detection of nucleic acid.

According to one aspect of the invention, a process for amplifying a specific nucleic acid sequence is used followed by the addition of two oligonucleotide probes—one with a binding species, the capture probe (i.e., biotin or antigen) and one with an electrochemiluminescent label.

The process involves the synthesis of single stranded RNA, single stranded DNA, and double stranded DNA. The single stranded antisense RNA is a first template for a second primer. The single stranded DNA is a second template for a first primer. The double stranded DNA is a third template for the synthesis of a plurality of copies of the first template. A sequence of the first or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. A second primer binds to the 3' end of the first RNA template and generates the second DNA template. A 3' end of the first primer hybridizes to the 3' end of the second DNA template. The second template is removed from the first template and is used to generate a complementary DNA strand. The resulting duplex DNA serves as a third template for synthesizing a plurality of first templates which in turn repeats the above described cycle. This process of amplification is described in detail by the following publications: Kievits et al., 35 J. Vir Method 273-286 (1991); Bruisten et al., 9 AIDS Res. and Human Retroviruses 259-265 (1993); EP 0 329 822-A2, WO 91/02818, WO 91/02814 (an essentially similar method is also described in WO 88/10315). On completion of the incubation, as described above, samples from the said amplification are taken and a mixture of complementary probes and beads coated in a binding species complementary to one of the probes in hybridization buffer is added followed by incubation at a predetermined temperature to allow the hybridization of the probes to the said first template and the binding of one of the said probes to the beads via a binding interaction, i.e., antibody-antigen or biotin-streptavidin. On completion of the said incubation, a complex is formed which comprises the said first template generated from the amplification reaction as above hybridized to two said differing probe, one containing an electrochemiluminescent label and the other a binding species. This complex is further complexed to said coated bead which forms its complementary binding pair with the probe binding species. The resulting complex contains the amplified first template, the probe with its electrochemiluminescent label, the capture probe with its binding species, and the bead with its coating of binding species (see Fig. 1) all complexed via the specific interactions of each component. It will also be understood that the DNA sequences generated during the NASBA cycling will be targets for hybridization and detection.

In another embodiment of the claimed invention, the interaction between the probe and the bead

can be made prior to the hybridization step by formation of a covalent bond to said bead or via a binding species (where said binding species is coated either by covalent or non-covalent methods) interaction or indirectly via a covalent bond to a species which can non-covalently coat said bead. An example of this indirect covalent coating could take the form of the probe being coupled to a carrier such as protein followed by coating via non-covalent methods to the bead surface.

In another embodiment, samples of the amplification would be mixed with a probe labeled with an ECL species and a bead which is coated with a binding species specific for the hybrid formed between said probe to the said amplified first template. For example, such a hybrid of DNA and RNA may be capture using a specific antibody. An example would be the use of a anti DNA:RNA antibody (Miles Inc. 4,833,084). Other antibodies which recognize such mixed hybrid molecules would also prove valuable such as those antibodies raised to hybrids of RNA or DNA to phosphonate, phosphorothioate, alkyl, or aryl phosphonate based nucleic acid sequences (Murakami et al., 24 Biochemistry 4041-4046 (1985), also available from Glenn Research, Sterling, Virginia). These methods are based on the formation of a new molecular species on hybridization which is a binding species for an antibody and raising antibodies or other binding species to these molecular species.

In yet another embodiment, the assay method may also be used to quantitate the amount of nucleic acid in the starting material. This is achieved by the addition to the samples of specific 'spike' samples which are amplified during the reaction. The determination of the spike signal and sample signal allows a ratio to be calculated, which based on the original spike level, allows the determination of the sample level. This is most accurately determined by the use of multiple spikes which range in amount over the range of the potential sample amounts and allow the construction of a standard curve to give a reading at a ratio of 1:1 between target and sample. Methods based on this are well understood-- Van Gemen et al., 43 J. Vir. Methods 177-187 (1993); Siebert and Larrick, 14 Biotechniques 244-249 (1993); Piatak et al., 14 Biotechniques 70-80 (1993). This method for quantitation is improved by the use of a rapid and accurate method for detection and quantitation provided by the use of the ECL labels and methods with the NASBA amplification.

The invention further provides a process for the detection of a specific nucleic acid sequence, comprising the steps of:

- (a) Providing a single reaction medium containing reagents comprising
 - (i) a first oligonucleotide primer,
 - (ii) a second oligonucleotide primer comprising an antisense sequence of a promoter,

- (iii) a DNA-directed RNA polymerase that recognizes said promoter,
- (iv) an RNA-directed DNA polymerase,
- (v) a DNA-directed DNA polymerase,
- (vi) a ribonuclease that hydrolyses RNA of an RNA-DNA hybrid without hydrolyzing single or double-stranded RNA or DNA,

(b) Providing in said reaction medium RNA comprising an RNA first-template which comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid sequence, under conditions such that a cycle ensues wherein

- (i) said first oligonucleotide primer hybridizes to said RNA first template,
- (ii) said RNA-directed DNA polymerase uses said RNA first template to synthesize a DNA second template by extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid intermediate,
- (iii) said ribonuclease hydrolyses RNA which comprises said RNA-DNA hybrid intermediate,
- (iv) said second oligonucleotide primer hybridizes to said DNA second template,
- (v) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize said promoter by extension of said DNA second template; and
- (vi) said DNA-directed RNA polymerase recognizes said promoter and transcribes said DNA second template, thereby providing copies of said RNA first template; and thereafter

(c) Maintaining said conditions for a time sufficient to achieve a desired amplification of said specific nucleic acid sequence, followed by the addition of;

- (i) at least one probe sequence complementary to said RNA first template labeled with an electrochemiluminescent species,
- (ii) at least one second capture probe sequence

complementary to said RNA first template labeled with a binding species,

(iii) a bead coated with a complementary binding species to said second probe sequence; and thereafter

5 (d) Providing conditions of temperature and buffer to allow the hybridization of the probes to the said RNA first template and the binding of said binding species on said second capture probe with the complementary binding species on said bead to form a bead bound complex; and then

(e) Detecting said bead bound complex using said electrochemiluminescent species.

10

The invention further provides a process for the detection of amplified products comprising the steps of :

(a) amplifying a sample nucleic acid under conditions to generate amplified product;

15

(b) mixing said amplified product with two binding species comprising

(i) an ECL labeled binding species which interacts with a trimolecular complex with the amplified nucleic acid and bivalent binding species;

20

(ii) a bivalent binding species which interacts with a trimolecular complex with the amplified nucleic acid and ECL labeled binding species;

to form a binding complex reaction;

25

(c) incubating said binding complex reaction under conditions which allow the formation of a trimolecular complex of amplified product, ECL labeled binding species, and bivalent binding species;

30

(d) capturing said trimolecular complex via the bivalent binding species' remaining binding site to a solid phase; and

(e) quantitating ECL label captured on the solid phase.

Definitions

In order to more clearly understand the invention, certain terms are defined as follows:

- 5 "Amplified product" means nucleic acid sequences generated by copying sample nucleic acid sequences multiple times using an enzymatic reaction.
- 10 "Annealing" refers to hybridization between complementary single chain nucleic acids when the temperature of a solution comprising the single chain nucleic acids is lowered below the melting or denaturing temperature.
- 15 "Binding species" means any species known to bind with another molecular species and are normally defined as a pair of species but may be formed from higher complexes, i.e., 3 or 4 which bind, i.e., antibody:antigen or oligonucleotide:antibody or oligonucleotide:antigen or DNA:DNA or DNA:RNA or RNA:RNA or DNA:RNA:DNA or Biotin-DNA:DNA-ECL labeled or receptor:ligand or DNA binding protein such as restriction enzymes, lac repressor.
- 20 The "complement" to a first nucleotide sequence is well known to be a second sequence comprising those bases which will pair by Watson-Crick hybridization with the first sequence. Thus, the complement to the deoxyribonucleic acid (DNA) sequence 5'ATGC 3' is well known to be 5'-GCAT 3'. For duplex, or double stranded DNA, each of the two strands are described as complementary to the other or as a complementary pair. The terms complement and anticomplement may also be used. With reference to the identification of the strand of duplex DNA from which transcription to RNA proceeds,
- 25 the transcription strand is generally described as plus and its complement as minus ("+" and "-"), or the transcription strand may be described as the sense strand, and its complement as antisense. Two strands each hybridized to the other having all base pairs complementary, are 100% complementary to each other. Two strands, each hybridized to the other, have 5% of bases non-complementary, are 95% complementary (or the two strands have 95% complementarity). In addition, it will also be understood
- 30 that nucleic acid sequences can form triple helix structures based on a specific interaction of three strands which would be considered to complementary in a specific way to each other within this triple stranded hybrid.

The terms "detection" and quantitation" are referred to as "measurement", it being understood that quantitation may require preparation of reference compositions and calibrations.

"Electrochemiluminescent (ECL) species" means any compound known to electrochemiluminescence;

5

"Electrochemiluminescent (ECL) labels" are those which become luminescent species when acted on electrochemically. Electrochemiluminescent techniques are an improvement on chemiluminescent techniques. They provide a sensitive and precise measurement of the presence and concentration of an analyte of interest. In such techniques, the sample is exposed to a voltammetric working electrode in order to trigger luminescence. The light produced by the label is measured and indicates the presence or quantity of the analyte. Such ECL techniques are described in PCT published application by Bard et al. PCT Appl. No. US 85/02153, entitled "Luminescent Metal Chelate Labels and Means for Detection" and Massey et al. PCT Appl. No. US 87/00987, entitled "Electrochemiluminescent Assays"; PCT Appl. No. US 88/03947, Publication No. WO 89/04302 "Electrochemiluminescent Moieties and Methods for Their Use"; Hall et al., "Method and Apparatus for Conducting Electrochemiluminescent Measurements", U. S. Appl. Ser. No. 744,890 filed August 14, 1991; and Zoski and Woodward. "Apparatus for Conducting Measurements of Electrochemiluminescent Phenomena", PCT US 89.04854 corresponding to pending EPO Appl. No. 89/912913.4, Publication No. 0441880.

10

15

20

25

Examples of ECL tags are tag NHS (N-hydroxy-succinimide) and tag phosphoramidite. The tag-NHS ester is useful for labeling substances containing free amino groups capable of reaction with the NHS ester to form an amide bond. (See, for example, WO 86/02734.) The tag phosphoramidite (Gudibande et al. U.S. Appl. Ser. No. 805,537 f entitled "Improved Electrochemiluminescent Label for DNA Probe Assay" which is hereby incorporated herein by reference) is useful for labeling substances containing free amino, sulphydryl, or hydroxyl groups forming phosphor-linkages especially phosphodiester linkages.

An "ECL assay buffer" is a general diluent which contains tripropylamine that is necessary for the electrochemical reaction on the electrode in an ECL analyzer.

30

An "ECL diluent" is a diluent reagent used in diluting solutions containing labile biomolecules for storage purposes.

"ECL apparatus" is any apparatus for performing electrochemiluminescence based assays. Such ECL

apparatus are described in PCT Appl. No. US 85/02153 by Bard et al. entitled "Luminescent Metal Chelate Labels and Means for Detection" and in PCT Appl. No. US 87/00987 by Massey et al. entitled "Electrochemiluminescent Assays" ; PCT Appl. No. US 88/03947, Publication No. WO 89/04302 "Electrochemiluminescent Moieties and Methods for Their Use"; Hall et al. "Method and Apparatus for Conducting Electrochemiluminescent Measurements", U. S. Appl. Ser. No. 744,890; and Zoski, G., and S. Woodward. "Apparatus for Conducting Measurements of Electrochemiluminescent Phenomena", PCT US 89.04854 corresponding to pending EPO Appl. No. 89/912913.4, Publication No. 0441880.

"Homology" between polynucleotide sequences refers to the degree of sequence similarity between the respective sequences. Two strands which are identical in sequence have 100% sequence homology. Two strands which differ by 5% of sequences have 95% sequence homology. The greater the degree of homology between two strands A and B, the greater the complementarity between A and the complement of B.

"Hybridization" describes the formation of double stranded or duplex nucleic acid from complementary single stranded nucleic acids. Hybridization may take place between sufficiently complementary single stranded DNA and/or RNA to form: DNA:DNA, DNA:RNA, or RNA:RNA or DNA:RNA:DNA or Biotin-DNA:RNA:DNA-ECL label. This may also include sequences of nucleotides which are linked using modified natural chemistries such as phosphonate, phosphorothioate, alkyl or aryl phosphonate based nucleic acid sequences (Murakami et al., Biochemistry 24 (1985):4041-4046, also Glenn Research, Sterling, Virginia).

The term "label" or "labeled" when applied to a nucleic acid means that the nucleic acid in question is linked to a moiety which is detectable by its properties which may include: ECL and luminescence, catalysis of an identifying chemical substrate, radioactivity, or specific binding properties. Thus, the term "label" includes ligand moieties unless specifically stated otherwise.

It is also well known to the art that the term "nucleic acid" refers to a polynucleotide of any length, including DNA or RNA chromosomes or fragments thereof with or without modified bases as described herein.

A "nucleotide" is at least one of the following bases: adenine, cytosine, guanine, thymine or uracil, plus a sugar (deoxyribose for DNA, ribose for RNA), plus a phosphate. In order to provide monomers for

the DNA polymerization reaction, typically all four of the deoxynucleotide triphosphates are required. A nucleotide, as defined herein, may also include modified bases such as 5-methyl-dCTP and 7-deaza-dGTP used to improve the action of polymerase on templates. The term nucleotide as used herein also includes bases linked to biotin and digoxigenin (Digoxigenin-11-UTP from Boehringer Mannheim, Indianapolis, Indiana) and biotin-21-UTP and amino-7-dUTP (Clontech, Palo Alto, California) and ECL labeled nucleotide (see Figs. 6 and 7) which may be incorporated directly into a primer or into a primer extension product during amplification, to provide for selective binding of amplified sequences.

An "oligonucleotide" is a sequence formed of at least two nucleotides.

A "polynucleotide" is a long oligonucleotide and may be either RNA and DNA.

While the term oligonucleotide is generally used in the art to denote smaller nucleic acid chains, and "polynucleotide" is generally used in the art to denote larger nucleic acid chains including DNA or RNA chromosomes or fragments thereof, the use of one or the other term herein is not a limitation or description of size unless expressly stated to be.

A "primer" is a relatively short segment of oligonucleotide which is complementary to a portion of the sequence of interest (the sequence of interest can be a subfragment within a larger nucleic acid sequence). A primer represents a 5' terminus of the resulting extension product. A primer which is complementary at its 3' terminus to the sequence of interest on the template strand enables this 3' terminus to be acted on by a polymerase on hybridization to the template. It is well known that modifications to the 3' end will affect the ability of an oligonucleotide to function as primer. An example is the incorporation of a dideoxynucleotide as in DNA sequencing thus preventing the action of DNA polymerases. It is well known that the length of the primer will depend upon the particular application, but that 20-30 base pairs is a common size. As is well known, a primer need not be a perfect complement for successful hybridization to take place. If the primer is an imperfect complement, an extension product will result which incorporates the primer sequence, and during a later cycle, the complement to the primer sequence will be incorporated into the template sequence. Thus, it is well known that a properly selected primer having a sequence altered from that of the complement of the template may be used to provide *in vitro* mutagenesis. The primer may incorporate any art known nucleic acid bases, including any art known modified or labeled bases as defined above so that the primer extension product will incorporate these features to permit separation and detection of the primer

extension product. A tag or marker advantageously linked to a primer may include an ECL fluorescent or luminescent tag, an isotopic (e.g., radioisotope or magnetic resonance) label, a dye marker, an enzyme marker, an antigenic determinant detectable by an antibody, or a binding moiety such as biotin enabling yet another indicator moiety such as a streptavidin coated bead to specifically attach to the primer or any nucleic acid sequence incorporating that primer. When the labeled or tagged amplification product is formed, that amplification product may be detected by the characteristic properties of the tag or label.

The term "primer extension product" describes the primer sequence together with the complement to the template produced during extension of the primer.

A "probe" is a single or double stranded nucleic acid which has a sequence complementary to a target nucleic acid sequence of interest and which has some additional feature enabling the detection of the probe -- target duplex. One skilled in the art will understand that if the probe and/or the target is double stranded, the double stranded nucleic acid must undergo strand separation before hybridization can take place. It is possible, if a triple strand formation is used, then the double stranded target will not need to be rendered single stranded prior to hybridization.

A probe is rendered detectable by an attached tag or marker. A tag or marker linked to a probe may include a fluorescent, ECL or luminescent tag, an isotopic (e.g., radioisotope or magnetic resonance) label, a dye marker, an enzyme marker, an antigenic determinant detectable by an antibody, or a binding moiety such as biotin enabling yet another indicator moiety such as a streptavidin coated bead to specifically attach to the probe. When the labeled or tagged probe--target duplex is formed, that duplex may be detected by the characteristic properties of the tag or label. Alternatively, as described for the ECL assays in the following examples, the probe with its binding moiety allows the capture of labeled target, via hybridization and duplex formation, allowing detection by a label or other art known means.

"Sample" means a mixture containing nucleic acids.

A "sequence" (e.g., sequence, genetic sequence, polynucleotide sequence, nucleic acid sequence) refers to the actual enumerated bases (e.g., ribose or deoxyribose) present in a polynucleotide strand (e.g., reading from the 5' and 3' direction) and the relative position of these bases with respect to each other.

The term "single primer" means a single, unpaired, specific or selected primer designed to selectively hybridize with a target nucleic acid sequence of interest.

5 "Specific nucleic acid sequence" means a single stranded or double stranded nucleic acid which one could use as a probe or amplify.

A "specific or selected" nucleotide sequence refers to a particular sequence distinguishable (i.e., by hybridization analysis) from other difference sequences (e.g., the specific nucleotide sequence 5'-ATGCCC-3' is not the same sequence as 5'-AAGCCC-3').

10

A specific or selected primer is one which is designed to hybridize with a particular template sequence to achieve the desired result by making the primer complementary or approximately complementary to the 3' terminal of the template sequence. The specific primer will selectively achieve the desired result even if the target template sequence is present in a mixture of many other nucleic acid sequences.

15

The specific or selected primer is distinguished from a "universal primer" which will indiscriminately anneal to any DNA sequence to which a complementary (to the primer) adaptor terminal sequence has been attached. With a universal primer, care must be taken to isolate the nucleic acid of interest, or otherwise direct the ligation procedure only to the desired DNA sequence of interest, to avoid randomly attaching the adaptor to all nucleic acid sequences present.

20

A "strand" is a single nucleic acid sequence. Thus, a duplex or double stranded chromosome, chromosome fragment or other nucleic acid sequence may be separated into complementary single strands.

25

"Strand separation" refers to the conversion of a double stranded or duplex nucleic acid to two complementary single stranded polynucleotide. The separation process may employ well known techniques including: enzyme mediated separation (e.g., by the enzyme helicase, physical-chemical separation (pH, ionic concentration and the like), and thermal separation also known as thermal denaturing. Thermal denaturing (also referred to as "melting") is the separation of a double stranded polynucleotide (fully or partially duplex) into at least two single strands of polynucleotide by raising the temperature of the solution holding that polynucleotide.

30

"Sufficiently complementary" means that two nucleic acids are capable of specific interaction which allows either a primer dependent and template directed synthesis of DNA or a probe to bind to nucleic acid sequence.

- 5 A "template" is any sequences of nucleic acid upon which a complementary copy is synthesized. This may, in general, be DNA to DNA replication, DNA to RNA transcription, or RNA to DNA reverse transcription. A DNA template provides the sequence information for extension of the complementary primer by the DNA polymerase reaction. An RNA template may provide the sequence information for extension of a complementary DNA primer by an analogous reaction catalyzed by the enzyme reverse transcriptase. As is well known to the art, the template may be found in a single or double stranded form. If the template enters the amplification process in the double stranded form, the template strand will not hybridize to its complementary primer until it is denatured by the first thermal denaturing cycle. If the template enters the amplification process already in the single stranded form, the primer will hybridize (described as annealing when thermal cycling is utilized) with its complementary template before the first thermal denaturing step.
- 10
- 15

Brief Description of the Drawings

- 20 Fig. 1 is a general illustration of the nucleic acid hybridization process.
- Fig. 2 is a general illustration of an alternative nucleic acid hybridization process.
- Fig. 3 is a general illustration of an alternative nucleic acid hybridization process.
- 25 Fig. 4 is a general illustration of an alternative nucleic acid hybridization process.
- Fig. 5 is a general illustration of an alternative nucleic acid hybridization process.
- 30 Fig. 6 is a general illustration of an alternative nucleic acid hybridization process.
- Fig 7 is an ECL labeled nucleotide.

Detailed Description of the Preferred Embodiments

This invention relates to a process for amplifying a specific nucleic acid sequence and its rapid detection and quantitation. The amplification involves an alternate synthesis for DNA and RNA. In this process, single stranded antisense (-) RNA is converted to single stranded DNA which in turn is converted to dsDNA and becomes a functional template for the synthesis of a plurality of copies of the original single stranded RNA. A first and a second primer are used in the amplification process. A sequence of the first primer or the second primer is sufficiently complementary to a sequence of the specific nucleic acid sequence and a sequence of the first or the second primer is sufficiently homologous to a sequence of the specific nucleic acid sequence. If the specific nucleic acid sequence is double stranded, then the primers can both be complementary and homologous. The detection, of the specific sequences which are amplified, is achieved by the use of probe sequences which form hybrids with the amplification products either DNA or RNA. These probe sequences are generally sufficiently complementary to a sequence of the specific nucleic acid sequence which results in the formation of a specific hybrid. These hybrids are then detected by the use of an ECL detection instrument which allows the ECL label to generate light in a controlled fashion at the surface of an electrode allowing both its detection and quantitation (Figs. 1, 2, 3, 4, 5, 6).

The assays for these amplified products is possible using a number of formats. The preferred method makes use of two probe molecules after the amplification process one is labeled with a binding species (i.e., biotin, digoxin, fluorescein), the other probe is labeled with an ECL label (i.e., Ru chelate, Os chelate, Re, Rh). These probes are added to the sample from the amplification reaction which generates a plurality of RNA copies of the original single stranded RNA or DNA and are complementary or sufficiently complementary to the plurality of RNA copies of the original single stranded RNA or DNA. This mixture of probes and amplified nucleic acid are allowed to hybridize by the control of the temperature and buffer components which are selected for the specific probe and plurality of RNA copies of the original single stranded RNA or DNA using methods known to those skilled in the art. The formation of these hybrids allows both probes to be linked in the same hybrid complex. These are then captured from the incubation by the addition of the magnetic beads which are coated with a binding species which binds to the binding species on the capture probe (Fig. 1). For example, with biotin on the probe streptavidin or avidin might be coated on to the magnetic beads or with digoxigenin on the probe an antibody specific for digoxigenin would be coated on the bead. This mixture of the hybrid complex and the bead would then be incubated under conditions known to promote the binding interaction of the binding species. These conditions for binding of binding species are well known to

those skilled in the art; for example, biotin to streptavidin or avidin and antigen antibody interactions.

Following the capture of the hybrid complex on the magnetic beads, the sample may be washed by capture of the beads by a magnet used in close proximity to the sample tube, or more ideally, the sample would be sampled directly into an ECL instrument which would capture the magnetic beads and its bound complex followed by the electrochemical reaction of the surface bound ECL label. The light generated from this electrochemical reaction is measured and used to determine the amount of ECL label which has formed a complex with the bead. This determination of the relative amounts of ECL label bound to the beads under certain conditions allows a determination of the amount of the plurality of RNA copies of the original single stranded RNA or DNA generated in the amplification. Using this information regarding the level of amplification of the specific DNA or RNA allows the diagnosis of the sample DNA or RNA for the presence of a specific DNA or RNA sequences which determine the presence of a gene and or organism in a sample.

Alternative to the above method, we may make use of two oligonucleotides which are labeled with binding species which allow the formation of a hybrid complex as described above but without a ECL label attached directly to the probe oligonucleotide. In this alternative format, the ECL label is linked to the hybrid complex either before hybridization to form said complex or after by the formation of a binding pair complex. Examples of such a system would be the use of a probe labeled with digoxin (binding species or antigen) and a probe labeled with biotin (binding species) these two probes would under well known conditions form a hybrid complex with the plurality of RNA copies of the original single stranded RNA or DNA generated in the amplification. After the formation of this hybrid complex, the addition of ECL labeled anti-digoxin antibody (complementary binding species or specific antibody) and streptavidin (complementary binding species) coated magnetic beads under conditions known to allow the formation of binding interactions (pH 4-9, 1mM to 2M salts, 0 to 10% detergents) allows the linkage of the ECL label to the hybrid complex by the binding of antigen to antibody. Also the complex is captured onto the surface of the bead via the binding interaction of streptavidin to biotin. The resulting extended complex of probes hybridized to the plurality of RNA copies of the original single stranded RNA or DNA generated in the amplification is then analyzed by the use of an ECL analyzer.

Alternatively, the formation of a specific complex labeled with an ECL species could be achieved by the use of a probe sequence labeled with an ECL species which when hybridized to the plurality of RNA copies of the original single stranded RNA or DNA generated in the amplification forms a binding species. This hybrid complex, or said binding species, is then captured by using complementary binding species coated magnetic beads followed by analysis using an ECL analyzer. For

example, antibodies to DNA:RNA hybrids (Fig. 2).

Alternatively, the amplification could be performed with a binding species such that said binding species are incorporated into the plurality of DNA and/or RNA molecules generated during the amplification process. Methods for this are well known to those skilled in the art. Examples of this could be the use of a primer (see primer 2, U.S. Patent No. 5, 130,238) modified to include a binding species said primer is then incorporated into the DNA+ strand by the action of RT on the RNA-species and primer 2. The DNA + product would be a DNA+ species covalently linked to a binding species molecule. This DNA-binding species molecule could then be hybridized to an ECL labeled probe and captured onto beads via a complementary binding species for ECL analysis (Fig. 4). In the same format, the DNA-binding species molecule could be captured onto a bead by hybridization, followed by binding to the DNA-binding species with a complementary binding species labeled with an ECL label. An example of the binding species could be biotin and its complementary binding species streptavidin. It will be understood that the RNA- and DNA+ (Fig. 1) could be labeled with a binding species by inclusion of a nucleotide as described earlier which is modified to incorporate a binding species for example biotin and digoxigenin (Digoxigenin-11-UTP from Boehringer Mannheim, Indianapolis, Indiana), and biotin-21-UTP and amino-7-dUTP (Clontech, Palo Alto, California) and ECL labeled nucleotides (Fig. 7) into the amplification reaction. The resulting DNA+ and/or RNA- binding species molecules can then be used in the assay formats as described above (Fig. 3).

Beads which are used in this assay are typically those from Dynal M450 and M280 coated with streptavidin but other beads can be used so long as the beads can be para-magnetic and are in the size range from 0.5 μm to 10 μm . It will be understood to one of ordinary skill in the art that the capture oligonucleotide could be coupled to these beads obviating the need for a binding species (Fig. 5).

Having now generally described the invention, the following examples are included for purposes of illustration and are not intended to limit the scope of the invention.

Examples

Example 1: Oligonucleotide Synthesis and Labeling

The oligonucleotides were made on an Applied Biosystems (San Jose, California) automated oligonucleotide synthesizer using the β -cyanoethyl phosphoramidite chemistry (Beaucage and Caruthers 22 Tetrahedron Lett. 1859-62 (1982)). Oligonucleotide amino modifications to the 5' end occurred at the last coupling step. Clontech (San Diego, California) supplied the amino modifiers, See U. S. Patent

5,141,813. The resulting 5' modified oligonucleotides all contain a six carbon spacer arm to the amino group, designated (C6, NH₂).

5
10
All the synthetic oligonucleotides were purified to remove any contaminating amino groups by gel filtration on a BIOGEL™ P6 (Bio-Rad Labs, Richmond, California) column. Biotin was introduced via the 5'-amino group of the oligonucleotides using NHS-biotin (Clontech, San Diego, California). Tag-NHS ester label (an NHS ester of the Ru tris bipyridyl complex) was introduced via the amino group of the modified oligonucleotides as follows. The oligonucleotides (0.1 μmole) in 100 μl of PBS (pH 7.4) were reacted with 0.5 μmole of tag -NHS ester label dissolved in DMSO overnight at room temperature in the dark. Oligonucleotides were recovered from these labeling reactions by ethanol precipitation. The modifications to the oligonucleotide and the labeling are indicated as follows.

Biotin:linker:'oligonucleotide' to indicate an oligonucleotide modified with a 5' amino group and then reacted with a biotin NHS reagent to yield a 5' biotinylated oligonucleotide. Also
15
R:linker:'oligonucleotide' to indicate an oligonucleotide modified with a 5' amino group and then reacted with the ruthenium tris bipyridine NHS reagent to yield a 5' ruthenium chelate oligonucleotide. Also 'oligonucleotide':linker:R to indicate an oligonucleotide modified with a 3' amino group and then reacted with the ruthenium tris bipyridine NHS reagent to yield a 3' ruthenium chelate oligonucleotide.

Probes for the Pol2 assay were as follows:

20
OT1, TTAAATTTTCCCATTAGCCCTATTGAGACT HIV1 Genbank; HIV BH102 #1900-1929 and
OT2, AGAAATCTGTTGACTCAGATTGGTTGCACT HIV1 Genbank; HIV BH102 #1869-1898.

These were made with the following modifications:

5OT1, Biotin:linker:TTAAATTTTCCCATTAGCCCTATTGAGACT

25
35OT1, R:linker:TTAAATTTTCCCATTAGCCCTATTGAGACT:linker:R

5OT2, Biotin:linker:AGAAATCTGTTGACTCAGATTGGTTGCACT

30
35OT2, R:linker:AGAAATCTGTTGACTCAGATTGGTTGCACT:linker:R.

Amplification was as described in J. Vir.. Methods 35 (1991):273.

Probes for the Gag3 assay were as follows:

Sequences for analysis of the HIV1 gag gene, Genbank HIVBH102 #1139-1167

AKZO1 TA GAA GAA ATG ATG ACA GCA TGT CAG GGA (29 bases)

5

HIVBH102 #1208-1236

AKZO2 CA`ATG AGC CAA GTA`ACA AAT ACA GCT ACC (29 bases).

10 made as:

AKZO1, Biotin:linker:TA GAA GAA ATG ATG ACA GCA TGT CAG GGA (29 bases) and

AKZO2, R:linker:CA ATG AGC CAA GTA ACA AAT ACA GCT ACC:linker:R (29 bases) for the gag3 assays below. The amplifications were performed or described in Van Gemen et al. 43 J. Vir. Methods 177-187 (1993).

15

Further probes for quantitative gag assays were as follows:

Probe A: TGT TAA AAG AGA CCA TCA ATG AGG A (25 bases) genbank ref. HIVBH102 #710-734.

Probe B: GAA TGG GAT AGA GTG CAT CCA GTG CAT G (29 bases) genbank ref. HIVBH102 #742-769.

20

Probe C: GAC AGT GTA GAT AGA TGA CAG TCG (24 bases) control sequence for quantitation as described in Van Gemen et al. J. Vir. Methods (1993).

25 The use of these probes A, B, and C would be as follows:

Using A as capture and B, C as detection or B, C as capture and A as detection.

To generate the needed probes, the following sequences were made incorporating biotin (binding species) and the ruthenium tri bipyridine complex (ECL label).

30

Probe A made as:

AKZO-A2, R:linker:TGT TAA AAG AGA CCA TCA ATG AGG A:linker:R

and as AKZO-A1, Biotin:linker:TGT TAA AAG AGA CCA TCA ATG AGG.

Probe B made as:

AKZO-B2, R:linker:GAA TGG GAT AGA GTG CAT CCA GTG CAT G:linker:R

and as AKZO-B1, Biotin:linker:GAA TGG GAT AGA GTG CAT CCA GTG CAT G.

5 Probe C made as:

AKZO-C2, R:linker:GAC AGT GTA GAT AGA TGA CAG TCG:linker:R

and as AKZO-C1, Biotin:linker:GAC AGT GTA GAT AGA TGA CAG TCG.

Where R is the ruthenium trisbipyridine N-hydroxy succinamide ester reacted to an amino group on the
10 oligonucleotide. The amino group introduced during synthesis.

Example 2: Preparation of Streptavidin Magnetic Beads

To 15 mg of BSA (in 2-3 ml PBS), 105 μ l of dimethylsulfoxide containing 50 mg/ml of biotin-x-
15 NHS (Clontech, San Diego, California) was added followed by mixing and incubation at room
temperature for 30 minutes. The reaction was stopped by adding 30 μ l of 1M glycine and incubation at
room temperature for 10 minutes. The reaction mix was purified by gel filtration chromatography (Bio-
Gel P6, Bio-rad Labs, Richmond, California). This biotin-BSA was filtered using a 0.2 μ m filter and
syringe. 5 mg biotin-BSA in 10 ml of 0.2 M sodium carbonate/bicarbonate buffer pH 9.6 was added to
20 300 mg of DYNABEADS™ (DYNAL No. 14002) (DYNABEADS is a trademark of DYNAL, Great
Neck, New York) The beads comprise either:

(i) Dynal M-450 Dynabeads, 4.5 μ m diameter superparamagnetic particles. 30 mg/mL,
obtained from Dynal, 45 North Station Plaza, Great Neck, New York 11021; or

25 (ii) Dynal M-280 Dynabeads, 2.8 μ m diameter superparamagnetic particles, 10 mg/mL,
obtained from Dynal, 45 North Station Plaza, Great Neck, New York 11021).

and washed with carbonate/bicarbonate. This mixture was vortexed and incubated overnight at room
30 temperature with mixing. The beads were magnetically separated followed by the addition of 10 ml
ECL diluent (37.5 mM KH_2PO_4 , 109.2 mM $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$, 151.7 mM CaCl_2 , 0.65 mM NaN_3 , 0.43 mM
bovine serum albumin in H_2O) and 100 μ l tRNA (10 mg/ml). This mixture was incubated for 3-4 hours
at room temperature with mixing. The beads were washed once with 10 ml of ECL diluent and

resuspended in 10 ml of ECL diluent and 100 μ l tRNA (10 mg/ml). This mixture was mixed and incubated at 2-6 °C overnight to stabilize proteins on beads. The beads were magnetically separated and suspended in 10 ml of phosphate buffered saline (PBS) containing 15 mg of streptavidin (Scripps Laboratories, San Diego, California, Catalog No. S1214) followed by mixing for one hour. The beads were washed 4 times in 10 ml ECL diluent, with 5 minutes mixing for each wash. The beads were finally resuspended in 29.7 ml of ECL diluent and 300 μ l tRNA (10 mg/ml) to a final concentration of 10 mg/ml particles + 100 μ g/ml tRNA.

Example 3: Pol 2 Assay

Probe solution I: for 50 assays we combined:

50 μ l of 35OT1 (ECL oligo at 1 μ g/ml),

50 μ l 5OT2 (biotin labeled oligonucleotide at 2 μ g/ml).

Amplifications were carried out using primers OT188 and OT42 following methods described in J. Vir. Method 35 (1991):273.

The samples were prepared by either of two methods:

A) 4 μ l of sample from amplification add 16 μ l of AKZO buffer containing 0.1% SDS, 20mM EDTA and heat for 5 minutes at 95°C.

B) 20 μ l of sample add 1.8 μ l of 1.25% SDS, 240 mM EDTA and heat for 5 minutes at 95°C.

In an assay tube, the following were combined: 5 μ l of probe solution I and 5 μ l of sample from above. These samples were incubated at 50 °C for 30 minutes followed by the addition of 5 μ l of beads (20 μ g Dynal 450) and mixed for 60 minutes. To this mixture 485 μ l of ECL assay buffer was added and the samples assayed in an ECL analyzer. The samples tested were 'NT' a no template control, 'A' 10 copies of HIV1 and 'B' 10,000 copies of HIV1. These were 1 μ l aliquotes from the amplification reaction.

The results were as follows:

<u>Sample</u>	<u>ECL signal</u>
Background signal	204
NT	1908
5	1884
	1913
A	1952
	1862
10	1911
B	175679
	179986
	167539

15

The results demonstrated the ability of the amplification and ECL to rapidly and sensitively detect the HIV 1 sequences. Example 4: Gag3 and Pol 2 Assay

20 To improve on the assay system as demonstrated above, we made use of more probe and beads to provide an assay with unparalleled range. Amplifications were carried out as in Example 3 and using primers OT83 and OT82 as described in 35 J. Vir. Method 273 (1991) for the gag gene.

Probe solution 1: for 50 pol2 assays we combined:

50 μ l of 35OT1 (ECL oligo at 20 μ g/ml),
 25 50 μ l 5OT2 (biotin labelled oligonucleotide at 20 μ g/ml).

Probe solution 2: for 50 gag3 assays we combined:

50 μ l of AKZO2 (ECL oligo at 20 μ g/ml),
 50 μ l of AKZO1 (biotin labelled oligonucleotide at 20 μ g/ml).

30

The samples were prepared by either of two methods:

A) 4 μ l of sample from amplification add 16 μ l of AKZO buffer containing 0.1% SDS, 20

mM EDTA and heat for 5 minutes at 95 °C.

- B) 20 μ l of sample add 1.8 μ l of 1.25% SDS, 240 mM EDTA and heat for 5 minutes at 95 °C.

5 Initial assay protocol in assay tube combine in the following order:

5 μ l of probe

5 μ l of sample.

10 Incubate at 50 °C for 30 minutes followed by the addition of 10 μ l of beads (40 μ g) and shaking for 60 minutes. These samples were diluted with ECL assay buffer 485 μ l and analyzed on an ECL analyzer. The samples tested were gag3 'G11', 10¹¹ copies of HIV1; 'G10', 10¹⁰ copies of HIV1; 'G9', 10⁹ copies of HIV1; 'G8', 10⁸ copies of HIV1; and 'BB' buffer blank for hybridization background.

15 These were samples of pure RNA generated as test samples containing this number of RNA molecules in the assay.

The results were as follows:

	Sample	ECL signal
20	Background signal	82
	G11	249559 252442
25	G10	12783 16059
	G9	1427 1429
30	G8	334 330

BB	250
	250

5 and pol2 samples from an amplification reaction which had used 10,000 copies of starting HIV1 sequences and estimated at 5×10^{10} copies per μl based on gel electrophoresis after amplification. This sample was diluted to determine the range of the new assay format for this sample. Samples were 'P10', 5×10^{10} ; 'P9', 5×10^9 ; 'P8', 5×10^8 ; 'P7', 5×10^7 ; 'P6', 5×10^6 , and 'BB' sample which has no amplified sample and controls for the non-specific binding in the assay.

10

The results were as follows:

<u>Sample</u>	<u>ECL signal</u>
Background signal	82
P10	58762
	62039
P9	4696
	4391
P8	677
	665
P7	330
	319
P6	254
	263
BB	250
	250

This experiment demonstrated the ability of the new assay format to function over at least 3.5 logs of sample concentrations and give a good linear response.

Example 5: Gag3

5

To improve on the assay system as demonstrated above we made use of more probe and beads to provide an assay with unparalleled range.

Probe solution 2: for 50 gag3 assays we combined:

- 10 50 μ l of AKZO2 (ECL oligo at 20 μ g/ml),
50 μ l of AKZO1 (biotin labeled oligonucleotide at 20 μ g/ml).

The samples were prepared by either of two methods:

- 15 A) 4 μ l of sample from amplification add 16 μ l of AKZO buffer containing 0.1% SDS, 20 mM EDTA and heat for 5 minutes at 95°C .
B) 20 μ l of sample add 1.8 μ l of 1.25% SDS, 240 mM EDTA and heat for 5 minutes at 95°C .

20 Initial assay protocol: in assay tube combine in the following order:

5 μ l of probe solution 2

5 μ l of sample.

- 25 Incubate at 50 °C for 30 minutes followed by the addition of 10 μ l of beads (40 μ g) and shaking for 60 minutes. These samples were diluted with ECL assay buffer 485 μ l and analyzed on an ECL analyzer. The samples tested were gag3 'G6', 10⁶ copies of HIV1; 'G5', 10⁵ copies of HIV1; 'G4', 10⁴ copies of HIV1; 'G3', 10³ copies of HIV1; 'G2', 10² copies of HIV1; 'G1', 10¹ copies of HIV1; and 'NT1', 'NT2', 'NT3' no template controls for background. The samples of these copy numbers were amplified as in Example 4 and 1 μ l analyzed for the presence of amplified sequences. Also a 'BB' sample which has no amplified sample and controls for the non-specific binding in the assay.
- 30

The results were as follows:

	<u>Sample</u>	<u>ECL signal</u>
5	G6	55870 56541
	G5	57798 58354
10	G4	66316 59120
	G3	74763 71190
15	G2	75315 69284
	G1	301 296
20	NT1	276 285
	NT2	283 295
25	NT3	312 283
	BB	272 289

Example 6: Patient Correlation Study

35 Samples of patients blood were fractionated and extracted to yield RNA for amplification. As in
 Example 4. This yielded samples from Whole blood (V), Platelets (T), Macrophages (M) and Plasma
 (P). These samples were amplified and subjected to Southern blot analysis with specific probes to
 determine the level and nature of the amplification from these samples. Samples from this amplification
 analysis were then subjected to analysis by the ECL system. In addition, standard samples generated *in*
 40 *vitro* were used as positive controls C2, 10^2 ; C3 10^3 ; C4, 10^4 ;

Probe solution 2: for 50 gag3 assays we combined:

50 μ l of AKZO2 (ECL oligo at 20 μ g/ml),

50 μ l of AKZO1 (biotin labeled oligonucleotide at 20 μ g/ml).

- 5 The 1 μ l samples were diluted to 5 μ l and made 0.1% SDS, 20mM EDTA and heated for 5 minutes at 95°C. This was followed by the addition of 5 μ l of probe solution. Incubated at 50°C for 30 minutes followed by the addition of 10 μ l of beads (40 μ g) and shaking for 60 minutes. These samples were diluted with ECL assay buffer 485 μ l and analyzed on an ECL analyzer.

10

ECL counts

	Patient Number	T	M	P	V
	203	100124	316769	154032	581
	204	499	227775	52619	310007
15	205	581	98188	501	75430
	206	510	368765	101581	524
	207	7990	251266	115186	81173
	208	533	254802	81832	288289
	C2	66644			
20	C3	138150			
	C4	146093			
	C5	125322			
	NT2	207099			
	NT3	581			
25	BB	605			
		605			

Further patient samples were analyzed.

ECL counts

	Patient Number	T	M	P	V
5	209	648	777	813	670
	210	672	261234	142876	162615
	211	237886	242394	187486	228249
	212	676	796	697	2802
	213	699	8004	152223	143648
10	228	592	173790	609	539
	C2	169992			
	C3	128430			
	C4	157989			
	C5	142345			
15	NT	575			
	NT2	209712			

All of this data correlated with the northern blot hybridization studies carried out on the amplified samples including the problems with the no templates showing problems with contamination. The assay did show evidence of a hook effect in sample 204P which gave higher results after dilution than with the 1 μ l of sample. This sample most likely has greater than the 10^{12} limit for the present assays linear response.

This data was followed up with assays on plasma isolated samples, split for gag3 assays and pol2 assays. Also samples were made from whole blood (V) and macrophages (M) where indicated.

GAG3 assay ECL peak signals.

	Sample	Sample volume used in the assay nl	20	1,000
	114		869	602
30	115		747	674
	116		756	646
	117		792	770
	118		735	709

	201 V	878	9651
	201	943	11149
	202 V	756	1592
	202	722	671
5	203	21370	196556
	204	11450	229730
	205	686	686
	206	11930	269703
	207	13996	151126
10	208	13217	259667
	209	663	585
	210	663	608
	211	30663	174421
	212	684	690
15	213	21257	227918
	228	703	568
	NT	869	627
	C2	3383	181566
	C3	37989	103653
20	C4	31531	106488
	37 V	1156	20282
	37 M	1602	53922
	41 V	8716	262440
	41 M	3579	192855
25	42 V	747	863
	42 M	739	806

POL2 assay ECL peak signals.

Sample volume used in the assay nl

20

1,000

Samples:

5	203	183	191
	204	24301	> 300000
	205	236	234
	206	217	278
	207	190	558
10	208	16232	> 300000
	209	15150	> 300000
	210	204	516
	211	3493	254728
	212	192	335
15	213	358	7773
	228	200	404
	NT	221	398
	C2	202	404
	C3	11893	> 300000
20	C4	17613	> 300000

This patient data correlated with previous northern blot analysis (Van Gemen et al., 45 J. Vir. Method (1993)).

Example 7

In addition to the above assay formats, we ran a set of samples in which all the components were added and hybridized, i.e., sample probes and beads these were incubated at 50 °C as previously and samples
5 taken from this mix at 5 through 30 minutes the signal was maximal at the 5 minute time point indicating the speed of the hybridization and flexibility of the assay system. The samples were a mix of two control amplified samples from 10^2 and 10^3 input template molecules these samples had been tested positive earlier. The NT was a sample which was negative.

10	Sample	Time (min)	ECL signal
	C2/C3mix	5.40	39200
		16.15	49025
		29.25	42960
	NT	7.40	863
15		22.15	1008
		> 30	853

WE CLAIM:

1. A process for the detection of a specific nucleic acid sequence, comprising the steps of:

- 5 (a) Providing a single reaction medium containing reagents comprising
- (i) a first oligonucleotide primer,
 - (ii) a second oligonucleotide primer comprising an antisense
sequence of a promoter,
 - (iii) a DNA-directed RNA polymerase that recognizes said
10 promoter,
 - (iv) an RNA-directed DNA polymerase,
 - (v) a DNA-directed DNA polymerase,
 - (vi) a ribonuclease that hydrolyses RNA of an RNA-DNA hybrid
without hydrolyzing single or double-stranded RNA or
15 DNA,
- (b) Providing in said reaction medium RNA comprising an RNA first-template which
comprises said specific nucleic acid sequence or a sequence complementary to said specific nucleic acid
sequence, under conditions such that a cycle ensues wherein
- (i) said first oligonucleotide primer hybridizes to said RNA
20 first template,
 - (ii) said RNA-directed DNA polymerase uses said RNA first
template to synthesize a DNA second template by
extension of said first oligonucleotide primer and thereby forms an RNA-DNA
hybrid intermediate,
 - (iii) said ribonuclease hydrolyses RNA which comprises said
25 RNA-DNA hybrid intermediate,
 - (iv) said second oligonucleotide primer hybridizes to said
DNA second template,
 - (v) said DNA-directed DNA polymerase uses said second
oligonucleotide primer as template to synthesize said
30 promoter by extension of said DNA second template; and
 - (vi) said DNA-directed RNA polymerase recognizes said
promoter and transcribes said DNA second template,

thereby providing copies of said RNA first template;
and thereafter

(c) Maintaining said conditions for a time sufficient to achieve a desired amplification of said specific nucleic acid sequence, followed by the addition of;

- 5 (i) at least one probe sequence complementary to said RNA first template labeled with an electrochemiluminescent species,
- (ii) at least one second capture probe sequence complementary to said RNA first template labeled with a binding species,
- 10 (iii) a bead coated with a complementary binding species to said second probe sequence; and thereafter

(d) Providing conditions of temperature and buffer to allow the hybridization of the probes to the said RNA first template and the binding of said binding species on said second capture probe with the complementary binding species on said bead to form a bead bound complex; and then

15

(e) Detecting said bead bound complex using said electrochemiluminescent species.

2. A process according to claim 1, wherein said RNA first template comprises said specific nucleic acid sequence and wherein step (B) comprises providing single-stranded RNA in said reaction medium such that

20

- (i) said first oligonucleotide primer hybridizes to said single-stranded RNA,
- (ii) said RNA-directed DNA polymerase uses said single-stranded RNA as a template to synthesize a DNA second template by extension of said first oligonucleotide primer and thereby forms an RNA-DNA hybrid,
- 25 (iii) said ribonuclease hydrolyses RNA which comprises said RNA-DNA hybrid,
- (iv) said second oligonucleotide primer hybridizes to said DNA second template,
- (v) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize said promoter by extension of said DNA second template; and
- 30 (vi) said DNA-directed RNA polymerase recognizes said promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

3. A process according to claim 1, wherein said RNA first template comprises a sequence complementary to said specific nucleic acid sequence and wherein step (B) comprises providing single-stranded RNA in said reaction medium such that

- (i) said second oligonucleotide primer hybridizes to said single-stranded RNA,
- 5 (ii) said RNA-directed DNA polymerase uses said RNA as a template to synthesize a complementary DNA by extension of said second oligonucleotide primer and thereby forms an RNA-DNA hybrid,
- (iii) said ribonuclease hydrolyses RNA which comprises said RNA-DNA hybrid,
- (iv) said first oligonucleotide primer hybridizes to said complementary DNA,
- 10 (v) said DNA-directed DNA polymerase uses said complementary DNA as template to synthesize said DNA second template and said promoter by extension of said first oligonucleotide primer; and
- (vi) said DNA-directed RNA polymerase recognizes said promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

4. A process according to claim 1, wherein step (B) comprises adding to said reaction medium single-stranded DNA which comprises an antisense sequence of said promoter, such that

- (i) said first oligonucleotide primer hybridizes to said single-stranded DNA,
- 20 (ii) said DNA-directed DNA polymerase uses said single-stranded RNA as a template to synthesize said DNA second template and said promoter by extension of said first oligonucleotide primer; and
- (iii) said DNA-directed RNA polymerase recognizes said promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

5. A process according to claim 4, wherein step (B) comprises adding to said reaction medium and RNA-DNA hybrid comprising said single-stranded DNA, such that said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid.

6. A process according to claim 1, wherein step (B) comprises adding to said reaction medium single-stranded DNA which comprises said DNA second template, such that

- (i) said second oligonucleotide primer hybridizes to said single-stranded DNA,
- 30 (ii) said DNA-directed DNA polymerase uses said second oligonucleotide primer as template to synthesize said promoter by extension of said DNA second template;

and

- (iii) said DNA-directed RNA polymerase recognizes said promoter and transcribes said DNA second template, thereby providing copies of said RNA first template.

- 5 7. A process according to claim 6, wherein step (B) comprises adding to said reaction medium and RNA-DNA hybrid comprising said single-stranded DNA, such that said ribonuclease hydrolyzes RNA which comprises said RNA-DNA hybrid.
8. A process according to claim 2, wherein step (B) comprises adding to said reaction medium a
10 DNA comprising said promoter, such that said DNA-directed RNA polymerase transcribes said DNA, thereby synthesizing said single-stranded RNA.
9. A process according to claim 3, wherein step (B) comprises adding to said reaction medium a
15 DNA comprising said promoter, such that said DNA-directed RNA polymerase transcribes said DNA, thereby synthesizing said single-stranded RNA.
10. A process according to claim 1, wherein said second oligonucleotide primer further comprises an antisense sequence of a transcription initiation site for said DNA-directed RNA polymerase, said antisense sequence of said transcription initiation site being operatively linked to said antisense sequence
20 of said promoter.
11. A process according to claim 1, wherein said RNA-directed DNA polymerase is a retrovirus reverse transcriptase.
- 25 12. A process according to claim 1, wherein said DNA-directed DNA polymerase lacks exonuclease activity.
13. A process according to claim 1, wherein all DNA polymerases in said reaction medium lack exonuclease and DNA endonuclease activity.
- 30 14. A process according to claim 1, wherein said DNA-directed DNA polymerase is DNA polymerase α or DNA polymerase β .

15. A process for the detection of amplified products comprising the steps of :

(a) amplifying a sample nucleic acid under conditions to generate amplified product;

(b) mixing said amplified product with two binding species comprising

(i) an ECL labeled binding species which interacts with a trimolecular complex with the amplified nucleic acid and bivalent binding species;

(ii) a bivalent binding species which interacts with a trimolecular complex with the amplified nucleic acid and ECL labeled binding species;

to form a binding complex reaction;

(c) incubating said binding complex reaction under conditions which allow the formation of a trimolecular complex of amplified product, ECL labeled binding species, and bivalent binding species;

(d) capturing said trimolecular complex via the bivalent binding species' remaining binding site to a solid phase; and

(e) quantitating ECL label captured on the solid phase.

16. A process according to claim 15 wherein said amplification conditions are isothermal.

17. A process according to claim 15 wherein said binding species is selected from the group consisting of an antibody:antigen, oligonucleotide:oligonucleotide, oligonucleotide:antibody, oligonucleotide:antigen, DNA:DNA, DNA:RNA, RNA:RNA, DNA:RNA:DNA, Biotin-DNA:DNA-ECL labeled, receptor:ligand, and DNA binding protein.

18. A process for the quantitative measurement of a sample comprising the steps of:

(a) amplifying an unknown sample with a known sample by the same primers, said known sample containing a non-homologous sequence to a sequence of said unknown sample, to

form a mixture of amplified product containing copies of the unknown sample and the known sample;

(b) taking said mixture of amplified product and separately quantitating the unknown sample and the known sample comprising the steps of:

(i) separately mixing the mixture of amplified product with two binding species, one specific for each of the known sample sequence and unknown sample sequence containing:

(1) an ECL labeled binding species which interacts with a trimolecular complex with the amplified nucleic acid and bivalent binding species;

(2) a bivalent binding species which interacts with a trimolecular complex with the amplified nucleic acid and ECL labeled binding species;

to form a binding complex reaction;

(c) incubating said binding complex reaction under conditions which allow the formation of a trimolecular complex of amplified product, ECL labeled binding species, and bivalent binding species;

(d) capturing said trimolecular complex via the bivalent binding species' remaining binding site to a solid phase; and

(e) quantitating ECL for said known sample and said unknown sample and then determine the amount of unknown sample in the unamplified starting reaction.

19. A process according to claim 18 wherein said amplification is isothermal.

20. A process according to claim 18 wherein said sample is selected from the group consisting of nucleic acids, amplified products, and synthetic DNA.

ABSTRACT

5 This invention relates to an improved process for detecting and quantifying a desired nucleic acid sequence. The process involves synthesizing single stranded RNA, single stranded DNA, double-stranded DNA followed by detection using an electrochemiluminescent labeled binding species.






Figure 1

Mix Sample and Reagents



Hybridization and Antibody binding



Binding and Reading






Figure 2

Mix Sample and Reagents



Amplified Target Molecules using
Biotinylated nucleotides

Hybridization



Binding and Reading






Figure 3

Mix Sample and Reagents



Amplified Target Molecules using
Biotinylated Primers

Hybridization



Binding and Reading






Figure 4

Mix Sample and Reagents



Hybridization



Binding and Reading






Figure 5

Mix Sample and Reagents



Hybridization



Binding and Reading





Figure 6



ECL labeled nucleotide for polymerase incorporation

Figure 7

FILE COPY

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Under 37 CFR § 1.63; includes reference to PCT International Applications)

IGEN, Inc., FILE NO. 9346

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the inventions: RAPID NUCLEIC ACID ASSAY, the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the date to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign/PCT Applications(s) [list additional application on separate page]:

Country (or PCT) Application Number: Filed (Day/Month/Year) Priority Claimed: Yes No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. (or U.S.-designating PCT) Application(s) [list additional application on separate page]:

U.S. Serial No. Filed (Day/Month/Year) PCT Application No. Status (patented, pending, abandoned)

CONFIDENTIAL

I hereby appoint John W. Ryan, Registration No. 33,771, and Barry Evans, Registration No. 22,802, and Curtis, Morris & Safford, P.C., Registration No. 12,761, or their duly appointed associate, my attorneys with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Court in connection therewith, and specify that all communications about the application are to be directed to the following correspondence address:

John W. Ryan, Esq.
IGEN, Inc.
1530 East Jefferson Street
Rockville, MD 20852

Direct all telephone calls to: (301) 984-8000
to the attention of:
John W. Ryan

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTORS:

Signature:

John H. Kenten

Date: 9/22/93

Full name of sole or first inventor: John H. Kenten
Residence: 1921 Windjammer Way, Gaithersburg, Maryland 20879
Citizenship: United Kingdom

Signature:

Rodger Smith

Date: 9/22/93

Full name of 2nd joint inventor (if any): Rodger Smith
Residence: 4660 Milford Court, Jefferson, Maryland 21755
Citizenship: United States

Post Office Addressee(s) of inventors [if different from residence]:

NOTE: In order to qualify for reduced fees available to Small Entities, each inventor and any other individual or entity having rights to the invention must also sign an appropriate separate "Verified Statement (Declaration) Claiming [or Supporting a Claim [or Supporting a Claim by Another for] Small Entity Status" form (e.g., for Independent Inventor, Small Business Concern, Nonprofit Organization, Individual Non-Inventor).